Hormonal therapy: Does it increase or decrease cardiovascular risk?

Obstetrical and Gynecological Survey

Volumn 61, Issue 10, 2006, Pages 673-681

  Schnatz, Peter F ^a,b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; TRIACYLGLYCEROL;

BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; HEART PROTECTION; HISTORY; HORMONAL THERAPY; HUMAN; INCIDENCE; MENOPAUSE; REVIEW; SURVIVAL; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

CARDIOVASCULAR DISEASES; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; PROGESTINS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 33749036565     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ogx.0000238674.98471.bb     Document Type: Review

References (41)

1. Supplemental material to Sacred Cows and Golden Geese (Greek and Greek), Specious Science (Greek and Greek), Brute Science (Lafollette and Shanks), and Animal Research in Light of Evolution (Shanks and Greek 2005). Available at: www.curedisease.com/internal_medicine.pdf (pp 15, 16) Accessed July 1, 2006.
2. Lawlor DA, Smith GD, Ebrahim S. Commentary. The hormone replacement and coronary heart disease conundrum: is this the death of observational epidemiology? Int J Epidemiol 2004;33:464-467.
3. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037.
4. Herrington DM, Espeland MA, Crouse JR, et al. Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Atheroscler Thromb Vasc Biol 2001;21:1955-1961.
5. Collins P, Rosano GMC, Sarrel PM, et al. Coronary heart disease/myocardial infarction: 17 beta-estradiol attenuates acetylcholine- induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995;92:24-30.
6. Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen? From bedside to bench. Circulation 1995;92:5-8.
7. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women (HERS). JAMA 1998;280:605-613.
8. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
9. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1995;273:199-208.
10. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
11. Schnatz PF, Schnatz JD. Dyslipidemia in menopause: mechanisms and management. Obstet Gynecol Surv. 2006;61:608-613.
12. Speroff L. Postmenopausal hormone therapy and cardiovascular disease: one view of the elephant. Menopause 2005;12:357-358.
13. Ostrzenski A, Ostrenska KM. WHI clinical trial revisit: imprecise scientific methodology disqualifies the study's outcomes. Am J Obstet Gynecol 2005;193:1599-1604.
14. Mendelsohn ME, Karas RH. The time has come to stop letting the HERS tale wag the dogma. Circulation 2001;104:2256-2259.
15. Herrington DM, Vittinghoff E, Lin F, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/progestin Replacement Study (HERS). Circulation 2002;105:2962-2967.
16. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
17. Kannel WB, Hjortland MC, McNamara PM, et al. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976;85:447-452.
18. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
19. Cherry N, Gilmour K, Hannaford P, et al. Estrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. The ESPRIT team. Lancet 2002;360:2001-2008.
20. Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with BJOG 2002;109:1056-1062.
21. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529.
22. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women: women's estrogen-progestin lipid-lowering hormone atherosclerosis regression trial research group. N Engl J Med 2003;349:535-545.
23. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-2440.
24. Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005;111:499-510.
25. Clarkson TB, Appt SE. Controversies about HRT - lessons from monkey models. Maturitas 2005;51:64-74.
26. Merz CNB, Johnson BD, Sharaf BL, et al. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. J Am Coll Cardiol 2003;41:413-419.
27. McGill HC, McMahan CA, Malcom GT, et al. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. Atheroscler Thromb Vasc Biol 1997;17:95-106.
28. Clarkson TB, Anthony MS, Klein KP. Hormone replacement therapy and coronary artery atherosclerosis: the monkey model. BJOG 1996;103(suppl 13):53-58.
29. Williams JK, Anthony MS, Honore EK, et al. Regression of atherosclerosis in female monkeys. Atheroscler Thromb Vasc Biol 1995;15:827-836.
30. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998;83:721-726.
31. Clarkson T, Anthony MS, Morgan TM. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab 2001;86:41-47.
32. Kaplan JR, Manuck SB, Anthony MS, et al. Premenopausal social status and hormone exposure predict postmenopausal atherosclerosis in female monkeys. Obstet Gynecol 2002;99:381-388.
33. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-941.
34. Grodstein F, Manson JE, Colditz, et al. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006;15:35-44.
35. Kronenberg F. Hot flashes. In: Lobo R, ed. Treatment of the Postmenopausal Woman, 2nd ed. New York: Lippincott Williams & Wilkins, 1999:158-160.
36. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Estrogen in the prevention of atherosclerosis trial research group. Ann Intern Med 2001;135:939-953.
37. Mendelson ME, Karas RH. Mechanisms of disease: the protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811.
38. Anderson GL, Limacher M, for the Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA 2004;291:1701-1712.
39. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease. Arch Intern Med 2006;166:357-365.
40. Salpeter SR, Walsh JME, Greyber E, et al. Brief report: coronary heart disease events associated with hormonal therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21:363-366.
41. Early versus Late Intervention Trial with Estradiol (ELITE). Available at: www.usc.edu/schools/medicine/research/centers_programs/aru/elite.html. Accessed July 1, 2006.